Michael K. Brawer

71 year

Health Technology

Consumer Services

Profile

Michael K.
Brawer served as Director at Northwest Prostate Institute and Vice President-Medical Affairs at Myriad Genetics, Inc. He was also the Chief Medical Officer at Threshold Pharmaceuticals, Inc. from 2003 to 2007 and the Chief Medical Officer & Executive Vice President at MDxHealth SA from 2017 to 2018.
Brawer received his undergraduate and doctorate degrees from the University of California, Los Angeles.

Former positions of Michael K. Brawer

Companies	Position	End
MDXHEALTH SA	Chief Tech/Sci/R&D Officer	2018-12-13
Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA	Chief Tech/Sci/R&D Officer	2007-11-01
Northwest Prostate Institute	Director/Board Member	-
MYRIAD GENETICS, INC.	Chief Tech/Sci/R&D Officer	-

See the detail of Michael K. Brawer's experience

Training of Michael K. Brawer

University of California, Los Angeles

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Michael K. Brawer's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
MYRIAD GENETICS, INC.	Health Technology
MDXHEALTH SA	Health Technology

Private companies	2
Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA	Health Technology
Northwest Prostate Institute